

DT03 Rec'd PCT/PTO
10/507,081
FEB 2005



PATENT
ATTORNEY DOCKET NO.: 056291-5178

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

NEWCOMBE et al.

Application No.: 10/507,081

Filed: September 9, 2004

FOR: DERIVATIVES OF 4-(IMIDAZOL-5-YL)-2-
(4-SULFOANILINO) PYRIMIDINE WITH
CDK INHIBITORY ACTIVITY

)
)
)
)
) Group Art Unit:
)
) Examiner:
)
)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop _____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: February 1, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Copies of the U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5178 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: February 1, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By: _____


Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date: February 1, 2005				Attorney Docket No.		Client Ref.	
				056291-5178			
				Applicant: NEWCOMBE et al.			
				Appln. No.: 10/507,081			
				Filing Date: September 9, 2004			
Examiner: Unassigned				Group Art Unit: Unassigned			

U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	
	AR						
	BR						
	CR						
	DR						
	ER						

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Enclosed	No	Enclosed	No	
	FR	98/16230	04/1998	WO	Horowitz et al.				
	GR	98/18782	05/1998	WO	Davis et al.				
	HR	98/33798	08/1998	WO	Boschelli et al.				
	IR	98/41512	09/1998	WO	Davis et al.				
	JR	98/54093	12/1998	WO	Bilodeau et al.				
	KR	98/56788	12/1998	WO	Bamborough et al.				
	LR	99/01136	01/1999	WO	Adams et al.				
	MR	99/18096	04/1999	WO	Desolms et al.				
	NR	99/18942	04/1999	WO	Alvi et al.				
	OR	99/31073	06/1999	WO	Hisamichi et al.		X		
	PR	99/32121	01/1999	WO	Gallagher et al.				
	QR	99/41253	08/1999	WO	Cushing et al.				
	RR	99/50250	10/1999	WO	Andries et al.				
	SR	99/50251	10/1999	WO	Griffin et al.				
**	TR	00/12485	03/2000	WO	Breault et al.				
**	UR	00/12486	03/2000	WO	Breault et al.				
	VR	00/17202	03/2000	WO	Calderwood et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)					
	WR				
	XR				
	YR				

Examiner	Date Considered:
----------	------------------

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.